SUPERB IDE Study Guide : IDEV Technologies

IDEV is leading the way in developing minimally invasive medical technologies to protect and preserve anatomical function.

IDEV is focused on products that are truly differentiated and deliver clear patient benefits.

IDEV is investing in research and development.

IDEV. Architects of Intervention.

Clinical

Publications

Case Reports

IDEV has completed enrollment in the SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery) IDE trial to evaluate SUPERA in treating patients with obstructive superficial femoral artery (SFA) disease.

SUPERB is a multicenter, prospective, non-randomized, single-arm study enrolling 258 patients at up to 50 sites. The primary efficacy endpoint is patency greater than 66% at 12 months, defined as freedom from restenosis (measured by duplex ultrasound) and TVR.

The principal investigators leading this study are nationally respected clinicians, Kenneth Rosenfield, M.D. of Massachusetts General Hospital and Lawrence A. Garcia, M.D. of Caritas St. Elizabeth's Medical Center.

For more information visit the SUPERB Study website, or click on the links below.

	SUPERB IDE Study Guide
	SUPERB Vessel Preparation and Stent Sizing Guide

SUPERA® is a different
class of stent.